Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in perioperative coagulation function during hip and knee replacement
ChiCTR1900021589Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Mar 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban and low molecular weight heparin calcium in venous thromboembolism (VTE) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Determination of anti-factor Xa activity, Thromboelastogram and 2 more. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
rivaroxabanlow molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR1900021589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021589.